Defective autophagy in fibroblasts may contribute to fibrogenesis in autoimmune processes

Current Pharmaceutical Design

Volumn 17, Issue 35, 2011, Pages 3878-3887

  del Principe, Domenico ^a,b   Vona, Rosa ^c   Giordani, Luciana ^c   Straface, Elisabetta ^c   Giammarioli, Anna Maria ^c  

^a Istituto San Raffaele   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Autoimmune diseases; Autophagy; Fibrosis; Systemic scleroderma

Indexed keywords

ADENYLATE KINASE; AZATHIOPRINE; BECLIN 1; CATHEPSIN B; CATHEPSIN D; CATHEPSIN L; CYCLOPHOSPHAMIDE; DEXAMETHASONE; EVEROLIMUS; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 4; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 2; MAMMALIAN TARGET OF RAPAMYCIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PREDNISONE; PROTEIN KINASE B; PROTEIN P53; RAPAMYCIN; RIDAFOROLIMUS; SPHINGOMYELIN; TEMSIROLIMUS; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

AUTOIMMUNE DISEASE; AUTOPHAGY; CYTOKINE PRODUCTION; FIBROBLAST; FIBROGENESIS; FIBROSIS; IMMUNOMODULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SCLERODERMA; SYSTEMIC SCLEROSIS;

EID: 83455203536     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161211798357791     Document Type: Review

References (130)

1. Davidson A, Diamond B. Autoimmune diseases. N Engl J Med 2001; 345: 340-50.
2. McCaughtry TM, Baldwin TA, Wilken MS, Hogquist KA. Clonal deletion of thymocytes can occur in the cortex with no involvement of the medulla. J Exp Med 2008; 205: 2575-84.
3. Klein L, Hinterberger M, Wirnsberger G, Kyewski B. Antigen presentation in the thymus for positive selection and central tolerance induction. Nat Rev Immunol 2009; 9: 833-44.
4. Mueller DL. Mechanisms maintaining peripheral tolerance. Nat Immunol 2010; 11: 21-7.
5. von Boehmer H, Melchers F. Checkpoints in lymphocyte development and autoimmune disease. Nat Immunol 2010; 11: 14-20.
6. Scofield RH. Autoantibodies as predictors of disease. Lancet 2004; 363: 1544-6.
7. Racanelli V, Prete M, Musaraj G, Dammacco F, Perosa F. Autoantibodies to intracellular antigens: Generation and pathogenetic role. Autoimmun Rev 2011; 10(8): 503-8.
8. Rosenthal M, Graf U, Müller W. Demonstration and analysis of immune complexes in rheumatic diseases. Schweiz Med Wochenschr 1976; 106: 1116-21.
9. Jelezarova E, Vogt A, Lutz HU. Interaction of C3b(2)-IgG complexes with complement proteins properdin, factor B and factor H: implications for amplification. Biochem J 2000; 349: 217-23.
10. Kivity S, Agmon-Levin N, Blank M, Shoenfeld Y. Infections and autoimmunity-friends or foes? Trends Immunol 2009; 30: 409-14.
11. Sfriso P, Ghirardello A, Botsios C, et al. Infections and autoimmunity: the multifaceted relationship. J Leukoc Biol 2010; 87: 385-95.
12. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell 2010; 140: 805-20.
13. Meneghin A, Hogaboam CM. Infectious disease, the innate immune response, and fibrosis. J Clin Invest 2007; 117: 530-8.
14. Raghow R. The role of extracellular matrix in post-inflammatory wound healing and fibrosis. Faseb J 1994; 8: 823-31.
15. Wick G, Backovic A, Rabensteiner E, Plank N, Schwentner C, Sgonc R. The immunology of fibrosis: innate and adaptive responses. Trends Immunol 2010; 31: 110-9.
16. Zhang K, Rekhter MD, Gordon D, Phan SH. Myofibroblasts and their role in lung collagen gene expression during pulmonary fibrosis. A combined immunohistochemical and in situ hybridization study. Am J Pathol 1994; 145: 114-25.
17. Molina V, Blank M, Shoenfeld Y. [Fibrotic diseases]. Harefuah 2002; 141: 973-8.
18. Mutsaers SE, Bishop JE, McGrouther G, Laurent GJ. Mechanisms of tissue repair: from wound healing to fibrosis. Int J Biochem Cell Biol 1997; 29: 5-17.
19. Buckley CD, Pilling D, Lord JM, Akbar AN, Scheel-Toellner D, Salmon M. Fibroblasts regulate the switch from acute resolving to chronic persistent inflammation. Trends Immunol 2001; 22: 199-204.
20. Levine B, Klionsky DJ. Development by self-digestion: molecular mechanisms and biological functions of autophagy. Dev Cell 2004; 6: 463-77.
21. Klionsky DJ. Abeliovich H, Agostinis P, et al. Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy 2008; 4: 151-75.
22. Deretic V. Autophagy as an immune defense mechanism. Curr Opin Immunol 2006; 18: 375-82.
23. Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell 2008; 132: 27-42.
24. Crotzer VL, Blum JS. Autophagy and adaptive immunity. Immunology 2010; 131: 9-17.
25. Rydell-Törmänen K, Uller L, Erjefält JS. Neutrophil cannibalism-a back up when the macrophage clearance system is insufficient. Respir Res 2006; 7: 143.
26. Matarrese P, Ciarlo L, Tinari A, Piacentini M, Malorni W. Xenocannibalism as an exacerbation of self-cannibalism: a possible fruitful survival strategy for cancer cells. Curr Pharm Des 2008; 14: 245-52.
27. Malorni W, Matarrese P, Tinari A, Farrace MG, Piacentini M. Xeno-cannibalism: a survival escamotage. Autophagy 2007; 3: 75-7.
28. Lleo A, Invernizzi P, Selmi C, et al. Autophagy: highlighting a novel player in the autoimmunity scenario. Autoimmun 2007; 29: 61-8.
29. Münz C. Antigen processing via autophagy-not only for MHC class II presentation anymore? Curr Opin Immunol 2010; 22: 89-93.
30. Paludan C, Schmid D, Landthaler M, et al. Endogenous MHC class II processing of a viral nuclear antigen after autophagy. Science 2005; 307: 593-6.
31. Delgado M, Singh S, De Haro S, et al. Autophagy and pattern recognition receptors in innate immunity. Immunol Rev 2009; 227: 189-202.
32. Levine B, Mizushima N, Virgin HW. Autophagy in immunity and inflammation. Nature 2011; 469: 323-35.
33. Fidziańska A, Bilińska ZT, Walczak E, Witkowski A, Chojnowska L. Autophagy in transition from hypertrophic cardiomyopathy to heart failure. J Electron Microsc 2010; 59: 181-3.
34. Sasaki M, Miyakoshi M, Sato Y, Nakanuma Y. Autophagy mediates the process of cellular senescence characterizing bile duct damages in primary biliary cirrhosis. Lab Invest 2010; 90: 835-43.
35. Vaquero EC, Rickmann M, Molero X. Tocotrienols: balancing the mitochondrial crosstalk between apoptosis and autophagy. Autophagy 2007; 3: 652-4.
36. Luna J, Masamunt MC, Rickmann M, et al. Tocotrienols have potent antifibrogenic effects in human intestinal fibroblasts. Inflamm Bowel Dis 2011; 17: 732-41.
37. Xie Z, Klionsky DJ. Autophagosome formation: core machinery and adaptations. Nat Cell Biol 2007; 9: 1102-9.
38. Hayashi-Nishino M, Fujita N, Noda T, Yamaguchi A, Yoshimori T, Yamamoto A. A subdomain of the endoplasmic reticulum forms a cradle for autophagosome formation. Nat Cell Biol 2009; 11: 1433-7.
39. Hamasaki M, Yoshimori T. Where do they come from? Insights into autophagosome formation. FEBS Lett 2010; 584: 1296-301
40. Nimmerjahn F, Milosevic S, Behrends U, et al. Major histocompatibility complex class II-restricted presentation of a cytosolic antigen by autophagy. Eur J Immunol 2003; 33: 1250-9.
41. Gannage M, Münz C. MHC presentation via autophagy and how viruses escape from it. Semin Immunopathol 2010; 32: 373-81.
42. Meijer AJ, Codogno P. Regulation and role of autophagy in mammalian cells. Int J Biochem Cell Biol 2004; 36: 2445-62.
43. Maiuri MC, Zalckvar E, Kimchi A, Kroemer G. Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat Rev Mol Cell Biol 2007; 8: 741-52.
44. Høyer-Hansen M, Jäättelä M. Autophagy: an emerging target for cancer therapy. Autophagy. 2008; 4: 574-80.
45. Martelli AM, Evangelisti C, Chiarini F, et al. The emerging role of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in normal myelopoiesis and leukemogenesis. Biochim Biophys Acta 2010; 1803: 991-1002.
46. Kroemer G, Mariño G, Levine B. Autophagy and the integrated stress response. Mol Cell 2010; 40: 280-93.
47. Arico S, Petiot A, Bauvy C, et al. The tumor suppressor PTEN positively regulates macroautophagy by inhibiting the phosphatidylinositol 3-kinase/protein kinase B pathway. J Biol Chem 2001; 276: 35243-6.
48. Criollo A, Maiuri MC, Tasdemir E, et al. Regulation of autophagy by the inositol trisphosphate receptor. Cell Death Differ 2007; 14: 1029-39.
49. Maiuri MC, Galluzzi L, Morselli E, Kepp O, Malik SA, Kroemer G. Autophagy regulation by p53. Curr Opin Cell Biol 2010; 22: 181-5.
50. Feng Z, Levine AJ. The regulation of energy metabolism and the IGF-1/mTOR pathways by the p53 protein. Trends Cell Biol 2010; 20: 427-34.
51. Klionsky DJ. Autophagy: from phenomenology to molecular understanding in less than a decade. Nat Rev Mol Cell Biol. 2007; 8: 931-7.
52. Mizushima N, Levine B, Cuervo AM, Klionsky DJ. Autophagy fights disease through cellular self-digestion. Nature 2008; 451: 1069-75.
53. Nakatogawa H, Oh-oka K, Ohsumi Y. Lipidation of Atg8: how is substratespecificity determined without a canonical E3 enzyme? Autophagy 2008; 4: 911-3.
54. Tanaka Y, Guhde G, Suter A, et al. Accumulation of autophagic vacuoles and cardiomyopathy in LAMP-2-deficient mice. Nature 2000; 406: 902-6.
55. Felbor U, Kessler B, Mothes W, Goebel HH, Ploegh HL, Bronson RT, et al. Neuronal loss and brain atrophy in mice lacking cathepsins B and L. Proc Natl Acad Sci USA 2002; 99: 7883-8.
56. Nishida Y, Arakawa S, Fujitani K, et al. Discovery of Atg5/Atg7- independent alternative macroautophagy. Nature 2009; 461: 654-8.
57. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006; 124: 471-84.
58. Feldman ME, Apsel B, Uotila A, et al. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 andmTORC2. PLoS Biol 2009; 7: e38.
59. Ravikumar B, Berger Z, Vacher C, O'Kane CJ, Rubinsztein DC. Rapamycin pre-treatment protects against apoptosis. Hum Mol Genet 2006; 15: 1209-16.
60. Rubinsztein DC, Gestwicki JE, Murphy LO, Klionsky DJ. Potential therapeutic applications of autophagy. Nat Rev Drug Discov 2007; 6: 304-12.
61. Fleming A, Noda T, Yoshimori T, Rubinsztein DC. Chemical modulators of autophagy as biological probes and potential therapeutics. Nat Chem Biol 2011; 7: 9-17.
62. Amaravadi RK, Lippincott-Schwartz J, Yin XM, et al. Principles and current strategies for targeting autophagy for cancer treatment. Clin Cancer Res 2011; 17: 654-66.
63. Grandér D, Kharaziha P, Laane E, Pokrovskaja K, Panaretakis T. Autophagy as the main means of cytotoxicity by glucocorticoids in hematological malignancies. Autophagy 2009; 5: 1198-2000.
64. Barton GM, Kagan JC. A cell biological view of Toll-like receptor function: regulation through compartmentalization. Nat Rev Immunol 2009; 9: 535-42.
65. Takeuchi O, Akira S. MDA5/RIG-I and virus recognition. Curr Opin Immunol 2008; 20: 17-22.
66. Inohara N, Chamaillard M, McDonald C, Nuñez G. NOD-LRR proteins: role in host-microbial interactions and inflammatory disease. Annu Rev Biochem 2005; 74: 355-83.
67. Palmer MT, Weaver CT. Autoimmunity: increasing suspects in the CD4+ T cell lineup. Nat Immunol 2010; 11: 36-40
68. Virgin HW, Levine B. Autophagy genes in immunity. Nat Immunol 2009; 10: 461-70.
69. Saitoh T, Akira S. Regulation of innate immune responses by autophagy- related proteins. J Cell Biol 2010; 189: 925-35.
70. Travassos LH, Carneiro LA, Ramjeet M, et al. Nod1 and Nod2 direct autophagy by recruiting ATG16L1 to the plasma membrane at the site of bacterial entry. Nat Immunol 2010; 11: 55-62.
71. Philpott DJ, Girardin SE. Nod-like receptors: sentinels at host membranes. Curr Opin Immunol 2010; 22: 428-34.
72. Bortoluci KR, Medzhitov R. Control of infection by pyroptosis and autophagy: role of TLR and NLR. Cell Mol Life Sci 2010; 67: 1643-51.
73. Lipinski MM, Hoffman G, Ng A, et al. A genome-wide siRNA screen reveals multiple mTORC1 independent signaling pathways regulating autophagy under normal nutritional conditions. Dev Cell 2010; 18: 1041-52.
74. Koble C, Kyewski B. The thymic medulla: a unique microenvironment for intercellular self-antigen transfer. J Exp Med 2009; 206: 1505-13.
75. Derbinski J, Kyewski B. How thymic antigen presenting cells sample the body's self-antigens. Curr Opin Immunol 2010; 22: 592-600.
76. Chaturvedi A, Pierce SK. Autophagy in immune cell regulation and dysregulation. Curr Allergy Asthma Rep 2009; 9: 341-6.
77. Uddin MN, Nishio N, Ito S, Suzuki H, Isobe KI. Autophagic activity in thymus and liver during aging. Age (Dordr) 2011 [Epub ahead of print].
78. Nedjic J, Aichinger M, Mizushima N, Klein L. Macroautophagy, endogenous MHC II loading and T cell selection: the benefits of breaking the rules. Curr Opin Immunol 2009; 21: 92-7.
79. Li C, Capan E, Zhao Y, et al. Autophagy is induced in CD4+ T cells and important for the growth factor-withdrawal cell death. J Immunol 2006; 177: 5163-8.
80. Pua HH, He YW. Maintaining T lymphocyte homeostasis: another duty of autophagy. Autophagy 2007; 3: 266-7.
81. Miller BC, Zhao Z, Stephenson LM, et al. The autophagy gene ATG5 plays an essential role in B lymphocyte development. Autophagy 2008; 4: 309-14.
82. Jia W, He YW. Temporal regulation of intracellular organelle homeostasis in T lymphocytes by autophagy. J Immunol 2011.
83. Barrett JC, Hansoul S, Nicolae DL, Cho JH, Duerr RH, Rioux JD, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet 2008; 40: 955-62.
84. Gateva V, Sandling JK, Hom G, et al. A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus. Nat Genet 2009; 41: 1228-33.
85. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006; 444: 860-7.
86. Mast BA, Schultz GS. Interactions of cytokines, growth factors, and proteases in acute and chronic wounds. Wound Repair Regen 1996; 4: 411-20.
87. Werner S, Grose R. Regulation of wound healing by growth factors and cytokines. Physiol Rev 2003; 83: 835-70.
88. Barrientos S, Stojadinovic O, Golinko MS, Brem H, Tomic-Canic M. Growth factors and cytokines in wound healing. Wound Repair Regen 2008S; 16: 585-601.
89. Hewitson TD, Becker GJ. Interstitial myofibroblasts in IgA glomerulonephritis. Am J Nephrol 1995; 15: 111-7.
90. Darby IA, Hewitson TD. Fibroblast differentiation in wound healing and fibrosis. Int Rev Cytol 2007; 257: 143-79.
91. Yan C, Grimm WA, Garner WL, et al. Epithelial to mesenchymal transition in human skin wound healing is induced by tumor necrosis factor-alpha through bone morphogenic protein-2. Am J Pathol 2010; 176: 2247-58.
92. Friedman SL. Mechanisms of disease: mechanisms of hepatic fibrosis and therapeutic implications. Nat Clin Pract Gastroenterol Hepatol 2004; 1: 98-105.
93. Keeley EC, Mehrad B, Strieter RM. The role of fibrocytes in fibrotic diseases of the lungs and heart. Fibrogenesis Tissue Repair 2011; 10: 4-2.
94. Clancy RM, Buyon JP. Autoimmune-associated congenital heart block: dissecting the cascade from immunologic insult to relentless fibrosis. Anat Rec A Discov Mol Cell Evol Biol 2004; 280: 1027- 35
95. Shao DD, Suresh R, Vakil V, Gomer RH, Pilling D. Pivotal Advance: Th-1 cytokines inhibit, and Th-2 cytokines promote fibrocyte differentiation. J Leukoc Biol 2008; 83: 1323-33.
96. Barron L, Wynn TA. Fibrosis is regulated by Th2 and Th17 responses and by dynamic interactions between fibroblasts and macrophages. Am J Physiol Gastrointest Liver Physiol 2011; 300: G723-8.
97. Wynn TA. Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat Rev Immunol 2004; 4: 583-94.
98. Yuan W, Yufit T, Li L, Mori Y, Chen SJ, Varga J. Negative modulation of alpha1(I) procollagen gene expression in human skin fibroblasts: transcriptional inhibition by interferon-gamma. J Cell Physiol 1999; 179: 97-108.
99. Lukacs NW, Hogaboam C, Chensue SW, Blease K, Kunkel SL. Type 1/type 2 cytokine paradigm and the progression of pulmonary fibrosis. Chest 2001; 120: 5S-8S.
100. Chizzolini C, Brembilla NC, Montanari E, Truchetet ME. Fibrosis and immune dysregulation in sistemi sclerosis. Autoimmun Rev 2011; 10: 276-81.
101. Wei J, Ghosh AK, Sargent JL, et al. PPARγ downregulation by TGFß in fibroblast and impaired expression and function in systemic sclerosis: a novel mechanism for progressive fibrogenesis. PLoS One 2010; 5: e13778.
102. Morishima Y, Ishii Y. Targeting Th2 cytokines in fibrotic diseases. Curr Opin Investig Drugs 2010; 11: 1229-38.
103. Ghadimi D, de Vrese M, Heller KJ, Schrezenmeir J. Lactic acid bacteria enhance autophagic ability of mononuclear phagocytes by increasing Th1 autophagy-promoting cytokine (IFN-gamma) and nitric oxide (NO) levels and reducing Th2 autophagy-restraining cytokines (IL-4 and IL-13) in response to Mycobacterium tuberculosis antigen. Int Immunopharmacol 2010; 10: 694-706.
104. Fairweather D, Cihakova D. Alternatively activated macrophages in infection and autoimmunity. J Autoimmun 2009; 33: 222-30.
105. Vellai T, Bicsák B, Tóth ML, Takács-Vellai K, Kovács AL. Regulation of cell growth by autophagy. Autophagy 2008; 4: 507-9.
106. Gabrielli A, Svegliati S, Moroncini G, Luchetti M, Tonnini C, Avvedimento EV. Stimulatory autoantibodies to the PDGF receptor: a link to fibrosis in scleroderma and a pathway for novel therapeutic targets. Autoimmun Rev 2007; 7: 121-6.
107. Trojanowska M. Noncanonical transforming growth factor beta signaling in scleroderma fibrosis. Curr Opin Rheumatol 2009; 21: 623-9.
108. Samuel GH, Bujor AM, Nakerakanti SS, Hant FN, Trojanowska M. Autocrine transforming growth factor β signaling regulates extracellular signal-regulated kinase 1/2 phosphorylation via modulation of protein phosphatase 2A expression in scleroderma fibroblasts. Fibrogenesis Tissue Repair 2010; 6: 3-25.
109. Kurasawa K, Hirose K, Sano H, et al. Increased interleukin-17 production in patients with systemic sclerosis. Arthritis Rheum 2000; 43: 2455-63.
110. Paintlia AS, Paintlia MK, Singh AK, Orak JK, Singh I. Activation of PPAR-γ and PTEN cascade participates in lovastatin-mediated accelerated differentiation of oligodendrocyte progenitor cells. Glia 2010; 58: 1669-85.
111. Aránguiz-Urroz P, Canales J, Copaja M, et al. Beta(2)-adrenergic receptor regulates cardiac fibroblast autophagy and collagen degradation. Biochim Biophys Acta 2011; 1812: 23-31.
112. Lam AP, Flozak AS, Russell S, et al. Nuclear ss-catenin is increased in SSc Pulmonary Fibrosis and Promotes Lung Fibroblast Migration and Proliferation. Am J Respir Cell Mol Biol 2011; 45(5): 915-22.
113. Wei J, Bhattacharyya S, Tourtellotte WG, Varga J. Fibrosis in systemic sclerosis: Emerging concepts and implications for targeted therapy. Autoimmun Rev 2011; 10: 267-75.
114. Xavier S, Gilbert V, Rastaldi MP, et al. BAMBI is expressed in endothelial cells and is regulated by lysosomal/autolysosomal degradation. PLoS One 2010; 5: e12995.
115. Pattingre S, Bauvy C, Levade T, Levine B, Codogno P. Ceramideinduced autophagy: to junk or to protect cells? Autophagy 2009; 5: 558-60.
116. Lavieu G, Scarlatti F, Sala G, et al. Is autophagy the key mechanism by which the sphingolipid rheostat controls the cell fate decision? Autophagy 2007; 3: 45-7.
117. Bu S, Asano Y, Bujor A, Highland K, Hant F, Trojanowska M. Dihydrosphingosine 1-phosphate has a potent antifibrotic effect in scleroderma fibroblasts via normalization of phosphatase and tensin homolog levels. Arthritis Rheum 2010; 62: 2117-26.
118. Rombouts K, Niki T, Greenwel P, et al. Trichostatin A, a histone deacetylase inhibitor, suppresses collagen synthesis and prevents TGF-beta (1)-induced fibrogenesis in skin fibroblasts. Exp Cell Res 2002; 278: 184-97.
119. Pang M, Zhuang S. Histone deacetylase: a potential therapeutic target for fibrotic disorders. J Pharmacol Exp Ther 2010; 335: 266-72.
120. Rishikof DC, Ricupero DA, Liu H, Goldstein RH. Phenylbutyrate decreases type I collagen production in human lung fibroblasts. J Cell Biochem 2004; 91: 740-8.
121. Ellis L, Pili R. Histone deacetylase inhibitors: advancing therapeutic strategies in hematological and solid malignancies. Pharmaceuticals (Basel) 2010; 3: 2411-69.
122. McEwan DG, Dikic I. The Three Musketeers of Autophagy: phosphorylation, ubiquitylation and acetylation. Trends Cell Biol 2011; 21: 195-201.
123. Ramser B, Kokot A, Metze D, Weiss N, Luger TA, Böhm M. Hydroxychloroquine modulates metabolic activity and proliferation and induces autophagic cell death of human dermal fibroblasts. J Invest Dermatol 2009; 129: 2419-26.
124. Schultz KR, Gilman AL. The lysosomotropic amines, chloroquine andhydroxychloroquine: a potentially novel therapy for graftversus- host disease. Leuk Lymphoma 1997; 24: 201-10.
125. Gilman AL, Chan KW, Mogul A, et al. Hydroxychloroquine for the treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2000; 6: 327-34.
126. Rahim R, Strobl JS. Hydroxychloroquine, chloroquine, and alltrans retinoic acid regulate growth, survival, and histone acetylation in breast cancer cells. Anticancer Drugs 2009; 20: 736-45.
127. Fried L, Kirsner RS, Bhandarkar S, Arbiser JL. Efficacy of rapamycin in scleroderma: a case study. Lymphat Res Biol 2008; 6: 217-9.
128. Dean PG, Grande JP, Sethi S, et al. Kidney transplant histology after one year of continuous therapy with sirolimus compared with tacrolimus. Transplantation 2008; 85: 1212-5.
129. Yoshizaki A, Yanaba K, Yoshizaki A, et al. Treatment with rapamycin prevents fibrosis in tight-skin and bleomycin-induced mouse models of systemic sclerosis. Arthritis Rheum 2010; 62: 2476-87.
130. Su TI, Khanna D, Furst DE, et al. Rapamycin versus methotrexate in early diffuse systemic sclerosis: results from a randomized, single- blind pilot study. Arthritis Rheum 2009; 60: 3821-30.